Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

• Published in: Journal of neurology Vol. 261; no. 6; pp. 1203 - 1209
• Main Authors: Kasai, Takashi, Tokuda, Takahiko, Ishii, Ryotaro, Ishigami, Noriko, Tsuboi, Yoshio, Nakagawa, Masanori, Mizuno, Toshiki, El-Agnaf, Omar M. A.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2014
• Subjects: 14-3-3 Proteins - cerebrospinal fluid; Adult; Aged; Aged, 80 and over; alpha-Synuclein - cerebrospinal fluid; Case-Control Studies; Creutzfeldt-Jakob Syndrome - cerebrospinal fluid; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Neurology; Neuroradiology; Neurosciences; Original Communication; ROC Curve; tau Proteins - cerebrospinal fluid; α-Synuclein; Tau; Biomarker; Cerebrospinal fluid; Creutzfeldt–Jakob disease; ELISA
• ISSN: 0340-5354; 1432-1459; 1432-1459
• DOI: 10.1007/s00415-014-7334-7

Recent studies have shown that cerebrospinal fluid (CSF) levels of α-synuclein (α-syn) are highly elevated in patients with Creutzfeldt–Jakob disease (CJD) compared to controls. However, the diagnostic value of CSF α-syn in CJD has not been established. To confirm whether CSF α-syn is increased in CJD and is a useful marker for this disease, two independent enzyme-linked immunoabsorbent assays (ELISAs) specific for α-syn were used: ELISA 211-FL140, which is specific for full-length α-syn, and ELISA N19-FL140, which is specific for the full-length and associated C-terminal truncated forms of α-syn. CSF samples from 24 patients with CJD and 24 controls were assessed in this study. We found that samples from the CJD patients showed significantly higher levels of CSF α-syn compared to controls in both ELISA (211-FL140 or N19-FL140) tests ( P  = 0.0467 and P  = 0.0010, respectively). However, there was a considerable overlap in the concentration ranges of the two groups of subjects. We also measured the levels of total tau (t-tau) protein in these samples and found that CSF t-tau levels were 5–10-times higher in the CJD group ( P  < 0.0001) compared with the controls. When the CSF t-tau and α-syn levels were combined, the area under the ROC curve (AUC) was slightly increased in clinically diagnosed CJD cases (AUC of 0.964) relative to an AUC of 0.943 for increased CSF t-tau alone. The combined use of CSF α-syn and t-tau levels may be a useful biomarker for the diagnosis of CJD.